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Introduction
Filamentous fungi such as Aspergillus, Penicillium 
and Talaromyces are some of the most exploited 
microbial sources for numerous bioactive compounds 
such as terpenes, statins, plant hormones, antifungals 
and anticancer agents. Polyketides represents one of the 
major classes of fungal bioactive products. One of the 
significant fungal polyketides with anticancer property 
belongs to the statin family. Statins are the world’s widely 
prescribed drugs to combat hypercholesterolemia and 
cardiovascular diseases. In addition, representatives of the 
statin group are known to possess antifungal properties 
against Saccharomyces spp., Candida spp., (Macreadie et 
al., 2006; Thorskov et al., 2013) and also anticancer, anti-
oxidant properties. Lovastatin, simvastatin, compactin 
etc are examples of statins. Commercial production of 
lovastatin employs Aspergillus terreus (Gulyamova et 
al., 2013).
For a drug to be tested for its bioactive properties, it 
needs be in the pure form. Most drugs are either purified 
by solvent extraction or by chromatography, thus meeting 
the safety standards of effective pharmaceuticals. While 
solvent extraction procedures are mostly used for easy 
and fast purification, chromatographic procedures 
have advantages over solvent extraction concerned to 
purity. Chromatographic purification can be achieved 
by adsorption chromatography using silica gel columns 
or by preparative thin layer chromatography and High 
Performance Liquid Chromatography (HPLC). Each 
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chromatography process has its own advantages and 
disadvantages, but adsorption chromatography using silica 
gel column is widely used because of its easy operation 
and high purity. Thus this technique of purification is 
employed in the present study (Ahmed et al., 2009). 
Lovastatin, other than its anticholesterol property, has 
diverse applications in the field of osteoporosis, neuro-
degeneration, rheumatoid arthritis, antifungals and also 
is reported to reduce proliferation of lung cancer cells, 
breast cancer (MCF-7), liver cancer (HepG2). HeLa 
cells are human epithelial cervical cancer cell line, and 
the first human cell line established in culture (Gey et 
al., 1952) and hence widely used for biological research 
(Landry et al., 2013). There are few reports available 
on the antiproliferative effects of lovastatin on cervical 
cancer (HeLa) cells and there are lesser reports about 
the effects of lovastatin with respect to its pro apoptotic 
effects and cell cycle regulation (Thorskov et al., 2013). 
Therefore the current study was undertaken to understand 
the proapoptotic effects of lovastatin on human cervical 
carcinoma cells (HeLa) as model system. Further, the 
ability of statins to prevent lipoprotein oxidation has also 
been investigated. Lovastatin, fluvastatin, atorvastatin 
and simvastatin exert antioxidant effects that protect cells 
against lipid peroxidation in vitro (Gotto et al., 2001). 
In the present study, lovastatin from Aspergillus 
terreus (KM017963) (Praveen et al., 2014) was purified by 
adsorption chromatography. Purified lovastatin was then 
evaluated for its proapoptotic and anti-oxidant property 
using HeLa cells, as an in vitro model, using several of 
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parameters.
Materials and Methods
Solid state fermentation 
Solid-state fermentation was performed in 500ml 
Erlenmeyer flasks containing 40g of wheat bran as 
substrate. The substrate was inoculated with spore 
suspension (107/8ml spores) of Aspergillus terreus 
(KM017963) with relative humidity (RH) of 70% and 
incubated at 28OC for 8 days (Jaivel and Marimuthu, 
2010).
Extraction
After eight days of incubation, the solid substrate 
was dried at 40oC for 24h, gently crushed and extracted 
with ethyl acetate by shaking at 180rpm for 2h followed 
by filtration through whatman No. 1 paper (Reddy et al., 
2011). The collected filtrate was concentrated by using 
rotary vacuum evaporator (Heidolph, Germany)
Chromatographic purification of lovastatin
The crude extract (reconstituted with 5ml of ethyl 
acetate) of lovastatin was loaded on to pre-packed column 
(300mm x 18mm) containing silica gel (60-120-mesh 
size). Elution was started with benzene (100%), followed 
by Benzene: Acetonitrile (95:5) till Acetonitrile (100%) 
was reached. Eluent was collected as 1 ml fractions. 
Each collected fraction was subjected to Thin Layer 
Chromatography (TLC) to detect the lovastatin fraction 
(Ahmed et al., 2009).
Thin Layer Chromatography (TLC)
The fractions obtained in column chromatography 
were applied to a heat activated 20×20 cm silica gel TLC 
plates. Dichloromethane and ethyl acetate (70:30, v/v) 
were used as mobile phase. All the plates were observed 
under Ultra Violet (UV) lamp (254 nm) after developing 
thrice in the same mobile phase and exposed to iodine 
vapour. For each TLC run, lovastatin authentic standard 
(Sigma-Aldrich, Germany) was spotted for Rf value 
comparison and confirmation (Praveen et al., 2014).
High Performance Liquid Chromatography (HPLC)
For HPLC, a C18 column (250mm x 4.6mm I.D micro 
metre) with diode array detector was used. Acetonitrile 
and water (acidified with 1.1% phosphoric acid) (70:30 
v/v) were used as mobile phase. The eluent flow rate 
was maintained at 1.5ml per min and detection carried 
out at 238nm with injection volume of 20μl (Samiee et 
al., 2003). The production of lovastatin is expressed in 
µg/g dry weight substrate (DWS). Purity was confirmed 
by presence of a single peak of lovastatin. The yield of 
lovastatin was calculated according to Muthumary and 
Sashirekha (2007). Mevinolin (M2147) (Sigma-Aldrich, 
Germany) was used as standard.
Cytotoxicity test by MTT assay
To determine cell viability, MTT based colorimetric 
assay was performed. Hela cells (1×104 cells/well) were 
cultured in a 96-well plate in DMEM or RPMI-1640 
medium at 37°C. Cells treated with culture medium served 
as a negative control. Cultured cells were treated with 
lovastatin at different concentrations (0-320µg/ml) and 
was incubated for 24h. Supernatant from each well was 
removed and washed twice with Phosphate buffered saline 
(PBS), 20μl of MTT solution (5 mgml-1 in PBS) and 100μl 
of medium were added, incubated for 4h for the formation 
of formazan crystals. The resultant crystals were dissolved 
in dimethyl sulfoxide (100μl) and the absorbance was 
measured using a microplate reader (Bio-RAD 680, USA) 
at 590 nm with a reference wavelength of 620 nm. All 
experiments were performed in triplicate, and the relative 
cell viability (%) was expressed as a percentage relative 
to the untreated control cells (Francois and Lang, 1986).
Hydroxyl Radical assay (Deoxyribose assay)
The deoxyribose assay was performed as described 
by Barry et al. (1987). The reaction volume of 1.0ml 
contained 5.6mM deoxyribose, 2.8 mM H2O2, 40μM 
FeCl3, 100μM EDTA, and varying concentrations of the 
purified lovastatin in 2.5mM phosphate buffer, pH 7.4. 
The reaction was initiated by addition of 0.1mM ascorbic 
acid and incubated for 90 min at 37°C. After incubation 
1ml of TBA (0.7% in 0.05N KOH) and 1ml of TCA 
(2.5%) was added. The mixture was heated to 100°C for 
8 min, cooled and the formed pink colored compound 
was measured at 532 nm. Corresponding controls were 
maintained that were devoid of lovastatin. Catechin was 
used as the reference standard.
GSH assay
Hela cells (104cells/well) seeded into 96 well plate 
and incubated for 24h. Lovastatin was added at varying 
concentrations and incubated for 24h. Cells were collected 
by centrifugation at 7000rpm for 5 min at 4ºC and 
supernatant was discarded. Cell pellet was re-suspended 
in 0.5ml ice-cold PBS and transferred into a 1.5 ml micro 
centrifuge tube and centrifuged at 7000rpm for 5min at 
4ºC. Supernatant was discarded. Cells were lysed in 80μl 
ice-cold glutathione buffer and incubated on ice for 10 
min. To this reaction mixture, 20μl of 5% Sulfosalicylic 
Acid (SSA) was added, mixed well and centrifuged at 
8000rpm for 10 min at 4oC. Supernatant was used for 
glutathione assay. To the supernatant, Ellman’s Reagent 
[5,5’-dithiobis-2-nitrobenzoic acid (DTNB)] was added, 
colour developed was measured at 412nm (Ellman, 1959).
Mitochondrial Membrane Potential Analysis (MMP)
Mitochondrial membrane potential was measured both 
qualitatively and quantitatively as described by Bishayee 
et al. (2013). After 48h incubation, control and lovastatin 
treated (150 μg/ml) cells (105cells/well) were fixed with 
2% paraformaldehyde and then incubated with 10μM 
rhodamine-123 for 30min at 37°C in dark. Cells were 
immediately analyzed using fluorescence microscopy 
[(OLYMPUS, Japan, omega filters-XF104), (~450nm and 
>670nm)]. To determine the mitochondrial membrane 
potential, fluorescence intensity of rhodamine-123 was 
assessed by a flow cytometer, (BD FACS Calibur, USA). 
Data obtained were analyzed. 
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Genotoxicity test by Comet assay
Cultured HeLa cells (106cells/well) were maintained 
in RPMI medium containing 10% foetal calf serum 
(FCS), 10000 U/l penicillin and 100mg/l streptomycin at 
37ºC, 5% CO2. Cultured cells were treated with different 
concentrations of lovastatin to check for the induction 
of DNA damage. Cells were washed briefly with PBS, 
trypsinized and suspended in medium with FCS to block 
the trypsin activity. Subsequently, cells were centrifuged 
for 10 min at 2000rpm. After removal of the medium, 
the cells were washed with PBS, centrifuged again, re-
suspended in PBS and diluted 1:4 with 1% agarose in PBS. 
Cell suspension (100µl) was mixed with 0.8% agarose 
which was added onto fully frosted slides with middle 
layer and sealed with a coverslip. After lysis 0.5% sodium 
dodecyl sulphate (SDS) and 33mM ethylene diamine 
tetra-acetic acid (EDTA) was added and incubated at 
room temperature (RT) for 40 min. Slides were then 
incubated for 10min in 1% Tris-Borate-EDTA (TBE) 
buffer (89mM Tris, 89mM boric acid and 0.2mM EDTA, 
pH 8.3). Electrophoresis of samples was carried out in 
TBE buffer at 1 V/cm.
For the alkaline assay, slides were incubated in 
alkaline lysis buffer (2.5M NaCl, 0.1 M EDTA, 10mM 
Tris-base, 0.2 M NaOH, 1% SDS, 1% Triton and 10% 
dimethyl sulphoxide) for 60 min at 4ºC. Subsequently, 
they were placed in electrophoresis buffer (0.3M NaOH 
and 1mM EDTA, pH 13) for 25min in order to unwind 
the DNA and electrophoresed at 1 V/cm for 25min or 2h, 
after electrophoresis slides were neutralized in Tris buffer 
(0.4M Tris–HCl, pH 7.5) for 5min (Jafari et al., 2013). 
Different parameters of DNA damage were analysed by 
open comet V.1.3 (USA) software.
Cell Cycle analysis 
HeLa cells (105cells/well) were cultured in a p35 
culture plate containing 1 ml of media. After 24h, cells 
were treated with different concentrations of lovastatin. 
Control cells were maintained that were not treated 
with lovastatin. Dimethyl Sulfoxide (DMSO) (1%) in 
1mlwell consisting of Dulbecco’s Modified Eagle Medium 
(DMEM) is taken as vehicle control. Above preparations 
were incubated for 18h. Post incubation, both floating and 
adherent cells were collected and pelleted at 1500rpm for 
5 min at RT and supernatant was discarded. The pellet 
was resuspended gently in 1X PBS. Cell pellet was fixed 
overnight at 4°C in 1000 μl of fixing solution (1X PBS 
in 70% ethanol). Centrifugation was carried at 1500rpm 
for 5min at RT and supernatant was discarded. Pellet 
was washed twice with cold PBS (1X). Cells were then 
incubated for 1h at RT in 500μl of Propidium Iodide 
(PI) solution containing 0.05mg/ml PI and 0.05mg/ml 
RNase-A in PBS. The percentage of cells in various stages 
of cell cycle in lovastatin treated and untreated populations 
was determined using fluorescence activated cell sorter 
(FACS) caliber (BD Biosciences, San Jose, CA) and 
analyzed by flow cytometry ( Flow Jo 7.5.5) (Tree Star 
Ashland OR) (Joany and O’Connor, 2001).
Statistical analysis
All experiments were done in triplicates and statistical 
analysis was performed by using SPSS, version 20. The 
statistical difference between mean values were assessed 
by one way analysis of variance (ANOVA) through 
Scheffe Post-Hoc test at a significance level of p<0.01
Results and Discussion
Lovastatin, by inhibiting HMG-CoA reductase, blocks 
cholesterol biosynthetic pathway (Seenivasan et al., 2008). 
Blocking the cholesterol synthesis also results in reduction 
of isoprenoid moieties of some protein. Thus lovastatin 
interferes with isoprenylation of proteins, which is a key 
regulatory step in many biological pathways. Therefore, 
besides its cholesterol lowering function, lovastatin also 
have pleiotropic roles in controlling of cell proliferation, 
apoptosis, survival and differentiation of cancerous cells 
(Shi et al., 2012). 
One of the goals of cancer therapy is to induce 
apoptosis in cancer cells. Numerous studies suggest that 
apoptosis is induced by exposure of tumor cells to statins 
(Jafari et al., 2013). In the present study, we observed that 
lovastatin produced by A. terreus (KM017963) exhibits 
cytotoxicity on cervical cancer cells (HeLa). This was 
evaluated by MTT assay, Mitochondrial Membrane 
Potential assay (MMP) and cell cycle analysis by flow 
cytometry. Genotoxicity was analyzed by comet assay 
and antioxidant effects of lovastatin were analyzed by 
hydroxyl radical scavenging assay and Glutathione (GSH) 
assay. 
Purification by column chromatography
Column chromatographic fractions when screened 
preliminarily by TLC. The fractions between 11-20 
Figure 1. Detection of Lovastatin in 80:20 fraction of 
Benzene:Acetonitrile by TLC. Lane 1:  Purified lovastatin 
from A. terreus (KM017963), Lane 2: Standard lovastatin
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obtained through column chromatography using Benzene: 
Acetonitrile (80:20) ratio, showed the presence of 
lovastatin (Figure 1). This was further confirmed by HPLC 
which showed a single, discrete peak (Figure 2). This 
purified fraction was used for further work i.e., to assess 
the anti-apoptotic and anti-oxidant property of lovastatin.
Effect of lovastatin on the growth and viability of HeLa 
cells-MTT assay
The purified lovastatin obtained from the above 
experiment was taken for all the studies carried out. 
Lovastatin treatments showed significant dose dependent 
cytotoxic effect on HeLa cells with IC50 value of 160 
µg/ml (Figure 3). These results indicated that lovastatin 
is a strong cytotoxic agent which partially explains its 
antitumor activity and can be suggested for the use as 
chemotherapeutic agent (Lucie et al., 2000). The probable 
reason for cytotoxicity of lovastatin is the attenuation of 
prenylation of signal proteins including small GTPase 
(Toshihiko et al., 2010).
Apart from lovastatin other statins are also reported 
to be cytotoxic by inducing apoptosis in cell lines of 
leukemia (Dimitroulakas et al., 2000), prostate cancer 
(Maltese et al., 1985), colon cancer (Agarwal et al, 1999), 
pancreatic cancer (Muller et al.,1998; Raghunath et al., 
2012). However, HeLa cells (30%) survived after 96 
hours in the presence of lovastatin (1μM) (Toshihiko et 
al., 2010).
Hydroxy radical scavenging activity of lovastatin
Since, MTT assay gave encouraging results showing 
reduced proliferation of HeLa cells, further investigations 
were performed to know whether lovastatin also exhibits 
Figure 4. Hydroxyl Radical Scavenging Activity of 
Standard Catechin and Lovastatin Respectively
Figure 5. Reduction (Percentage) of Total GSH in 
Lovastatin-Treated HeLa Cells
Figure 6. Propidium Iodide Staining of Untreated 
(Control) and Lovastatin Treated HeLa Cells
            Control (untreated)                       Treated with lovastatin             Contr l (untreated)                       Treated with lovastatin 
Figure 7. Comet Assay Analysis of Untreated (Control) 
and Lovastatin Treated HeLa Cells
Figure 2. Quantification of Purified Lovastatin by High 
Performance Liquid Chromatography (HPLC)
Figure 3. Percentage Inhibition of HeLa Cells 
Indicating Cytotoxic Effects of Lovastatin
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antioxidant property. Therefore, the radical scavenging 
assay and total reduced glutathione assays were carried 
out. 
As flavonoids are known for its antioxidant property, 
catechin (a flavonoid) was selected as a positive control. 
Hydroxyl radicals are generated in the reaction mixture 
using ascorbic acid–iron EDTA complex. Decreased 
absorbance of reaction mixture signifies increased 
scavenging activity, as the system prevents uncontrolled 
formation of hydroxyl free radicals generated by cancer 
cells which can lead to death of healthy cells, tissues, 
membrane peroxidation, DNA modification, enzyme 
inactivation, and oxidation of proteins (Mohan kumari 
et al., 2011). Thus lovastatin was effective to accelerate 
hydroxyl radical scavenging activity (54.06%) at an IC50 of 
3601µg/ ml as compared to its positive control (catechin) 
which showed 86.86% at an IC50 value of 350.5µg/ml 
(Figure 4).
There are many reports of lovastatin exhibiting 
antioxidant properties, inhibiting lipid peroxidation 
(Ajith et al., 2006), however there are very few reports 
of lovastatin scavenging for hydroxyl radicals. Other 
than lovastatin, all other statins tested, showed significant 
antioxidant activity against both peroxyl and hydroxyl 
radicals. Fluvastatin was the most active anti-oxidant 
among statins toward peroxyl radicals, while simvastatin 
was active against hydroxyl free radicals (Ferdinando et 
al., 2003).
Effect of lovastatin on total reduced Glutathione (GSH)
Glutathione (GSH) is a tripeptide formed by glutamic 
acid, cysteine, and glycine. GSH plays an important 
role in a many cellular processes, which include cell 
differentiation, proliferation, apoptosis, antioxidant 
defenses and progression of diseases like cancer. GSH 
levels are observed to increase in tumor cells, which make 
the neoplastic tissues resistant to chemotherapy. Hence 
in the current study the levels of GSH was determined 
to understand whether the inhibitory effects of lovastatin 
observed on growth of HeLa cells was also accompanied 
by a depletion in the levels of total reduced glutathione 
in the cells (Traverso, 2013). 
However, in our study, lovastatin showed moderate 
reduction in total reduced glutathione (41.58%) as 
compared to its positive control (ascorbic acid) which 
showed 68.85% at an IC50 value of 19.46µg/ml (Figure 
5). Thus, treatment with lovastatin could be very effective 
to sensitize tumor cells to cytotoxic/apoptotic effects of 
specific anticancer agents, by depleting GSH, thereby 
inhibiting GSH-mediated cell protective effect offered 
to the cancer cells. However, reduced GSH may induce 
antioxidant enzymes which could cause death of normal 
cells, but lovastatin prevents the exertion of oxidative 
stress caused by free radicals on cells by inhibiting lipid 
peroxidation (Mohankumari et al., 2011).  
Effect of lovastatin on DNA damage and fragmentation 
-Comet assay
Increased DNA synthesis and cell proliferation are 
generally regarded as characteristic features of cancers 
and current therapy focuses on DNA fragmentation of 
these cancer cells.
Thus, result of the comet assay implicated that 
lovastatin showed moderate DNA fragmentation at 
Figure 8. Flow Cytometric Analysis of HeLa Cells 
Treated with Lovastatin
PI-Fluorescence
Figure 9. Cell Growth Arrest (Percentage) of HeLa 
Cells by Purified Lovastatin at SubG0/G1, G0/G1, S 
and G2/M phases
Figure 10. Fluorescence Microscopic Images of 
Untreated and Lovastatin Treated HeLa Cells
Figure 11. Flow Cytometric Analysis of Rh123 Treated 
HeLa Cells (Control) and Rh123 Treated HeLa Cells 
Exposed to Lovastatin
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320µg/ml (Figure 6) and most common parameters of 
comet assay are analysed by opencomet software. This 
study was carried out to establish which measurement(s) 
in the comet assay are significantly correlated with DNA 
damage (Figure 7). The observed DNA fragmentation may 
be attributed to the depletion of intracellular mevalonate 
as observed by Choi and Jung(1999) in C6 glial cells.
Effect of lovastatin Mitochondrial Membrane Potential 
(MMP) of HeLa cells
This study was performed to check the effect of 
lovastatin through its intrinsic pathway involving the 
mitochondria. Hela cells treated with lovastatin at 150µg/
ml, showed significant decrease in uptake (10.03%) of 
Rhodamine 123 (Rh123) as compared to untreated cells 
which showed 80%. Fluorescence microscopy and flow 
cytometry analysis of rhodamine treated HeLa cells are 
shown in Figure 10 and Figure 11 respectively.
The mitochondria of healthy cells maintain an 
electrochemical gradient in its inner membrane created by 
the movement of protons across its transmembrane space 
called mitochondrial membrane potential (MMP) (Lincoln 
et al., 1981). Deregulation of this cellular pH (MMP) of 
mitochondrial transmembrane of HeLa cells by lovastatin 
results in cell death. Reduction in MMP could be due to 
the opening of the mitochondrial permeability transition 
pores, resulting in the release of proteins and cytochrome 
C into the cytosol, which in turn triggers other downstream 
events in the apoptotic cascade leading to apoptosis 
of cells. (Matsuyama and Reed, 2000). Mitochondria-
rhodamine specific interaction is dependent on the high 
MMP which is maintained by functional mitochondria. 
Thus uptake of rhodamine 123 (a fluorescent dye) is 
decreased due to reduction in MMP (Lincoln et al., 1981).
Effect of lovastatin on cell cycle arrest of HeLa cells
Further, results of all the above assays incited us to 
verify the cell cycle arrest pattern of lovastatin on HeLa 
cells. Flow cytometric analysis of lovastatin treated HeLa 
cells showed suppressed proliferation which was evident 
at 320µg/ml of lovastatin. 
The cell cycle distribution in cultures exposed to a 
cytostatic concentration of lovastatin was unchanged 
during the initial 6h of treatment. However, as the time 
of exposure to lovastatin increased, the proportion of 
cells in S phase progressively decreased concomitant 
with an increase in G1-phase cells. Hence, lovastatin 
suppressed growth of Hela cells. Cells show cell cycle 
arrest of 20.09% and 24.67% at SubG0/G1 phase at the 
concentration of 160 and 320µg/ml respectively compared 
to the untreated cells (0.0%). However, arrest at G2/M 
phase of cell cycle is not much different as compared 
to untreated cells with above mentioned concentration 
(Figure 9). This result suggests that lovastatin do not allow 
the cells to proceed from G0/G1 to next phase of cell 
cycle and at the same time it might induce the apoptosis. 
This induced apoptosis may be due to elevation of some 
cell cycle inhibitors that have been reported to suppress 
cell cycle progression, resulting in G0/G1 phase arrest 
in HeLa cells (ref). It is also possible that inhibition of 
isoprenylation of certain proteins by lovastatin may be 
responsible for the suppression of cell growth (Jakobisiak 
et al., 1991).
Further, lovastatin is also reported to cause G1 phase 
arrest in Swiss 3T3 mouse fibroblast cells (Poon et al., 
1995). These effects of lovastatin could be due to the 
induction of multiple intrinsic stress pathway in HeLa 
cells, which happens either by activation of certain stress 
response like caspases or inhibiting some growth factors 
(Laurie et al., 2012). Cell growth arrest may also be 
attributed to the down-regulation of cyclin dependent 
kinase (CDK 2) activity and cytostatic activity of 
lovastatin that could be mediated by the closed ring form 
of lovastatin by affecting proteasome function (Wong et 
al., 2002). Also, cells in the late G0 and G1/G2 phases of 
the cell cycle are reported to be most sensitive to cell death 
when exposed to ionizing radiation, whereas cells in S 
phase are most resistant. Thus, G1 phase cell cycle arrest, 
induced by lovastatin can potentially sensitize HeLa cells 
to radiation, making the radiation therapy more effective 
(shibata et al., 2004). 
In conclusion, the present study adds to the 
understanding that lovastatin is not only capable of 
reducing cardiac disease related mortality but also could 
be a potential anticancer agent. This is in agreement 
with previous reports that lovastatin reduces cancer 
incidence worldwide by 28-33% (Julie et al., 1997; Elena 
et al., 2008; Linda et al., 2010). Results also suggest the 
probable use of lovastatin in association with conventional 
treatment as apoptosis-triggering agents in HeLa cells as 
statins demonstrate to potentiate the antitumor activity 
of some cytokines. However, the interaction between 
lovastatin and chemotherapeutic agents could be a field of 
considerable research interest in future. Overall, lovastatin 
from A.terreus (KM017963) gives supporting evidence as 
an agent for chemotherapy of cervical cancer.
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